Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
Completed
Cephalon
Phase 2
The purpose of the study is to determine whether CEP-701 given in sequence with induction
chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML)
who achieve a second complete remission (CR).
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
Completed
National Cancer Institute (NCI)
Phase 1
RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating
young patients with recurrent or refractory high-risk neuroblastoma.
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
Completed
New Approaches to Neuroblastoma Therapy Consortium
Phase 1
RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for
their growth.
PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating
young patients with recurrent or refractory high-risk neuroblastoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
